Boston Scientific Corporation vs D Wave Quantum Inc — how do they compare? Boston Scientific Corporation trades at $51.4 (market cap $74.19B), while D Wave Quantum Inc trades at $20.58 (market cap $7.53B). The key difference: Boston Scientific Corporation is far larger — about 9.9× D Wave Quantum Inc's market cap, and D Wave Quantum Inc is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | QBTS | |
|---|---|---|
Market Cap | $74.19B | $7.53B |
Sector | Health | Technology |
52-Week High | $108.14 | $44.78 |
52-Week Low | $42.63 | $12.98 |
Enterprise Value | $86.27B | $7.04B |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $51.27, up 1.6% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats in 2026, with Q2 EPS of $0.86 exceeding expectations. Revenue grew to $20.07B in 2025 with a 14.4% net margin, while analyst consensus shows 86% buy ratings with a $67.21 price target. Recent insider buying by the CEO and director signals confidence despite near-term guidance challenges.
BSX presents attractive valuation with 44% upside to consensus target, supported by strong fundamentals and institutional support. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with elevated RSI levels suggesting potential near-term consolidation. The long-term growth trajectory remains intact with 2026 revenue projected at $21B and 17.5% margins.
QBTS trades at $20.55, up 1.78% today, with a bearish technical signal despite 100% analyst buy ratings. The stock shows extreme valuation with a P/S of 583.84 and negative profitability, including a net income margin of -2,001.59% for 2026. Recent Q2 2026 earnings missed revenue and EPS estimates, though bookings surged 1,120%, highlighting growth potential amid financial strain. Cash flow trends indicate heavy investment outlays, with net cash flow turning negative in 2026.
Outlook remains speculative; the consensus price target of $38.29 offers significant upside, but high execution risks persist. Investors face volatility from unproven commercial scaling, reliance on financing, and competitive quantum computing pressures. The stock's appeal hinges on future revenue conversion from bookings, making it suitable for risk-tolerant investors betting on long-term quantum adoption.
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →